trending Market Intelligence /marketintelligence/en/news-insights/trending/RG-pP5PuntBHJBAXs7Tzfw2 content esgSubNav
In This List

Arbutus Biopharma regains Nasdaq compliance

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

Blog

Commercial Banking Newsletter June Edition - 2022


Arbutus Biopharma regains Nasdaq compliance

Arbutus Biopharma Corp. regained compliance with the Nasdaq Stock Market's listing standards after appointing Daniel Burgess as a director and the third member of its audit committee.

The company received a notice of noncompliance after Frank Karbe resigned from the board's audit committee, leaving the audit committee one member short of Nasdaq's listing requirements.